These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20628091)

  • 1. A prospective study of calcaneal bone mineral density in acute Charcot osteoarthropathy.
    Petrova NL; Edmonds ME
    Diabetes Care; 2010 Oct; 33(10):2254-6. PubMed ID: 20628091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes.
    Petrova NL; Foster AV; Edmonds ME
    Diabet Med; 2005 Jun; 22(6):756-61. PubMed ID: 15910628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study.
    Jansen RB; Christensen TM; Bülow J; Rørdam L; Holstein PE; Jørgensen NR; Svendsen OL
    J Diabetes Complications; 2018 Feb; 32(2):164-170. PubMed ID: 29196119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover.
    Jirkovská A; Kasalický P; Boucek P; Hosová J; Skibová J
    Diabet Med; 2001 Jun; 18(6):495-500. PubMed ID: 11472470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy.
    Petrova NL; Dew TK; Musto RL; Sherwood RA; Bates M; Moniz CF; Edmonds ME
    Diabet Med; 2015 Feb; 32(2):267-73. PubMed ID: 25251588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in diabetes mellitus patients with and without a Charcot foot.
    Christensen TM; Bülow J; Simonsen L; Holstein PE; Svendsen OL
    Clin Physiol Funct Imaging; 2010 Mar; 30(2):130-4. PubMed ID: 20089075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density.
    Herbst SA; Jones KB; Saltzman CL
    J Bone Joint Surg Br; 2004 Apr; 86(3):378-83. PubMed ID: 15125125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density during total contact cast immobilization for a patient with neuropathic (Charcot) arthropathy.
    Hastings MK; Sinacore DR; Fielder FA; Johnson JE
    Phys Ther; 2005 Mar; 85(3):249-56. PubMed ID: 15733049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charcot osteoarthropathy of the foot.
    Perrin BM; Gardner MJ; Suhaimi A; Murphy D
    Aust Fam Physician; 2010 Mar; 39(3):117-9. PubMed ID: 20369111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charcot osteoarthropathy in type 2 diabetes persons presenting to specialist diabetes clinic at a tertiary care hospital.
    Younis BB; Shahid A; Arshad R; Khurshid S; Masood J
    BMC Endocr Disord; 2015 Jun; 15():28. PubMed ID: 26065885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral and central bone mineral density in Charcot's neuroarthropathy compared in diabetic and nondiabetic populations.
    Greenhagen RM; Wukich DK; Jung RH; Vardaxis V; Yoho RM
    J Am Podiatr Med Assoc; 2012; 102(3):213-22. PubMed ID: 22659764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of off-loading and recurrence rate in Charcot osteo-arthropathy treated with less restrictive regimen with removable walker.
    Christensen TM; Gade-Rasmussen B; Pedersen LW; Hommel E; Holstein PE; Svendsen OL
    J Diabetes Complications; 2012; 26(5):430-4. PubMed ID: 22699112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal blood flow response and vasomotion in the diabetic Charcot foot.
    Shapiro SA; Stansberry KB; Hill MA; Meyer MD; McNitt PM; Bhatt BA; Vinik AI
    J Diabetes Complications; 1998; 12(3):147-53. PubMed ID: 9618070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy.
    Gough A; Abraha H; Li F; Purewal TS; Foster AV; Watkins PJ; Moniz C; Edmonds ME
    Diabet Med; 1997 Jul; 14(7):527-31. PubMed ID: 9223389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot.
    Jansen RB; Svendsen OL
    J Diabetes Complications; 2018 Jul; 32(7):708-712. PubMed ID: 29857955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory osteolysis in diabetic neuropathic (charcot) arthropathies of the foot.
    Sinacore DR; Hastings MK; Bohnert KL; Fielder FA; Villareal DT; Blair VP; Johnson JE
    Phys Ther; 2008 Nov; 88(11):1399-407. PubMed ID: 18801857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.
    Jude EB; Selby PL; Burgess J; Lilleystone P; Mawer EB; Page SR; Donohoe M; Foster AV; Edmonds ME; Boulton AJ
    Diabetologia; 2001 Nov; 44(11):2032-7. PubMed ID: 11719835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Charcot neuro-osteoarthropathy.
    Petrova NL; Edmonds ME
    Diabetes Metab Res Rev; 2016 Jan; 32 Suppl 1():281-6. PubMed ID: 26451965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent inflammation with pedal osteolysis 1year after Charcot neuropathic osteoarthropathy.
    Sinacore DR; Bohnert KL; Smith KE; Hastings MK; Commean PK; Gutekunst DJ; Johnson JE; Prior FW
    J Diabetes Complications; 2017 Jun; 31(6):1014-1020. PubMed ID: 28254346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confronting a dramatic situation: the charcot foot complicated by osteomyelitis.
    Dalla Paola L
    Int J Low Extrem Wounds; 2014 Dec; 13(4):247-62. PubMed ID: 25123373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.